Highlights of weekly biotech stock moves

Amgen Inc. (NASDAQ:AMGN) gained $0.67 to $82.03 last week after FDA approved an sBLA for Prolia denosumab to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is already approved in the U.S. and EU to treat osteoporosis in postmenopausal women and in the EU to treat bone loss associated with hormone ablation in men with prostate cancer. The product is approved in the U.S. and EU as Xgeva to prevent skeletal related events in adults with bone metastases from solid tumors.

Celgene Corp. (NASDAQ:CELG) was up $1 to $77.27 last week after announcing FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Nov. 8 to discuss an NDA for pomalidomide in combination with dexamethasone to treat patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. Pomalidomide has a Feb. 10, 2013, PDUFA date...